Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RND1
- Development stage
- Preclinical
- Lead developer
- Lineage Cell Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
01
Overview
RND1 is a preclinical-stage hypoimmune induced pluripotent stem cell (iPSC) line being developed by Lineage Cell Therapeutics in collaboration with Factor Bioscience. The cell line is engineered using gene-editing technology to reduce immunogenicity, facilitating the creation of allogeneic (off-the-shelf) cell transplant therapies. Key genetic modifications include the targeted deletion of the Beta-2-microglobulin (B2M) gene to inhibit rejection by CD8+ T cells and the targeted insertion of the HLA-E gene to prevent adverse natural killer (NK) cell responses. A third undisclosed genetic edit is also included to provide clinical differentiation and a competitive advantage. RND1 is intended for differentiation into cell transplant product candidates for the treatment of central nervous system (CNS) diseases and other neurological indications.
- Other names
- RND1RND-1RND 1
02
Targets
B2M (Beta-2-microglobulin)HLA-E (Human leukocyte antigen-e)
Beyond the preview
Go deeper on RND1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RND1.